I agree that this site is using cookies. You can find further informations here.
X
Dylla, Douglas E
91  results:
Search for persons X
?
1

Assessment of Drug–Drug Interaction Risk Between Intravenou..:

Mukherjee, Dwaipayan ; Collins, Michelle ; Dylla, Douglas E....
Infectious Diseases and Therapy.  12 (2023)  8 - p. 2057-2070 , 2023
Link: https://doi.org/10.1007/..
 
?
2

Reported adverse events related to use of hepatitis C virus..:

Martinez, Anthony ; Khan, Tipu ; Dylla, Douglas E....
Harm Reduction Journal.  20 (2023)  1 - p. , 2023
Link: https://doi.org/10.1186/..
 
?
3

Shorter Duration Hepatitis C Virus Treatment is Associated ..:

Martinez, Anthony ; Cheng, Wei-Han ; Marx, Steven E....
Advances in Therapy.  40 (2023)  8 - p. 3465-3477 , 2023
Link: https://doi.org/10.1007/..
 
?
4

Safety analysis of glecaprevir/pibrentasvir in patients wit..:

Feld, Jordan J. ; Forns, Xavier ; Dylla, Douglas E....
Journal of Viral Hepatitis.  29 (2022)  12 - p. 1050-1061 , 2022
Link: https://doi.org/10.1111/..
 
?
5

Healthcare resource utilization in Hepatitis C-infected pat..:

Valdez, Katia E. ; Javanbakht, Marjan ; Keith, Kori...
Frontiers in Gastroenterology.  1 (2022)  - p. , 2022
Link: https://doi.org/10.3389/..
 
?
6

Positive predictive value of sustained virologic response 4..:

Gane, Edward ; de Ledinghen, Victor ; Dylla, Douglas E....
Journal of Viral Hepatitis.  28 (2021)  11 - p. 1635-1642 , 2021
Link: https://doi.org/10.1111/..
 
?
7

Epidemiology and Clinical Characteristics of Individuals wi..:

Reau, Nancy ; Sulkowski, Mark S. ; Thomas, Emmanuel...
Advances in Therapy.  38 (2021)  12 - p. 5777-5790 , 2021
Link: https://doi.org/10.1007/..
 
?
8

Safety of Patients with Hepatitis C Virus Treated with Glec..:

Forns, Xavier ; Feld, Jordan J. ; Dylla, Douglas E....
Advances in Therapy.  38 (2021)  6 - p. 3409-3426 , 2021
Link: https://doi.org/10.1007/..
 
?
9

Awareness and Epidemiology of Chronic Hepatitis C Virus Inf..:

Thomas, Emmanuel ; Cheng, Wei-Han ; Dylla, Douglas E....
Infectious Diseases and Therapy.  11 (2021)  1 - p. 451-462 , 2021
Link: https://doi.org/10.1007/..
 
?
10

High Sustained Virologic Response Rates of Glecaprevir/Pibr..:

Zamor, Philippe J. ; Brown, Ashley ; Dylla, Douglas E....
American Journal of Gastroenterology.  116 (2021)  9 - p. 1896-1904 , 2021
Link: https://doi.org/10.14309..
 
?
11

Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatm..:

Flamm, Steven L. ; Kort, Jens ; Marx, Steven E....
Advances in Therapy.  37 (2020)  5 - p. 2267-2274 , 2020
Link: https://doi.org/10.1007/..
 
?
12

Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is S..:

Zuckerman, Eli ; Gutierrez, Julio A. ; Dylla, Douglas E....
Clinical Gastroenterology and Hepatology.  18 (2020)  11 - p. 2544-2553.e6 , 2020
Link: https://doi.org/10.1016/..
 
?
13

Lentiviral Vector Gene Transfer to Porcine Airways:

Sinn, Patrick L ; Cooney, Ashley L ; Oakland, Mayumi...
Molecular Therapy - Nucleic Acids.  1 (2012)  - p. e56 , 2012
Link: https://doi.org/10.1038/..
 
?
14

Altering α-dystroglycan receptor affinity of LCMV pseudotyp..:

Dylla, Douglas E ; Xie, Litao ; Michele, Daniel E..
Genetic Vaccines and Therapy.  9 (2011)  1 - p. , 2011
Link: https://doi.org/10.1186/..
 
?
15

689. Restriction Profiles of Primate TRIM5α on FIV:

Dylla, Douglas E. ; Hickey, Melissa A. ; Hatziioannou, Theodora..
Molecular Therapy.  13 (2006)  - p. S266-S267 , 2006
Link: https://doi.org/10.1016/..
 
1-15